A post hoc ALPACA analysis presented at ESC Congress 2026 shows lepodisiran cut Lp(a)-bound oxidized phospholipids by up to 94% at the 400-mg dose.
Steven E. Nissen, MD, MACC
Advertisement
Steven Nissen, MD, of Cleveland Clinic
Articles by Steven E. Nissen, MD, MACC
Steven Nissen, MD, shares key takeaways on AAV8, CTX310, and Kylo-11 gene and molecular therapies presented at ESC Congress 2026.
Nissen discusses his post-hoc analysis of the SURPASS-CVOT trial, comparing the 2 drugs for a 6-component composite endpoint of cardiorenal outcomes.
Steve Nissen, MD, discusses the phase 2 ALPACA trial and how it informs the potential of lepodisiran for lowering Lp(a).
Advertisement
Latest Updated Articles
Lepodisiran Reduces OxPL Tied to Lp(a), With Steven Nissen, MDSeptember 4th 2026
Advertisement
Advertisement
Trending on HCPLive
1
Tilrekimig Meets EASI-75 Goal in Atopic Dermatitis, With Eric Simpson, MD
2
Tips on Optimizing HS Biologics, Combinations, and Surgery
3
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
4
FAQ: ASH's New Ferritin Thresholds, With Jacquelyn Powers, MD, MS
5